IL33 and gastric cancer: Before testing the cell cycle gene expression after the treatment with rhIL-33 on ex vivo samples, we checked the expression of IL-33 and its receptor ST2 on biopsies collected from patients who had undergone endoscopy and were classified as healthy control (HC; N = 48) and gastric cancer patients (GC; N = 16) (Table 3).